UBS
19/11/2019
1
$30.00
22.95%
- COMMENTARY
Appen has upgraded 2019 guidance for operating earnings (EBITDA) to $97-101m. The upgrade is being driven by strength in the core Relevance business and largely from existing projects.
UBS calculates the Relevance business is growing at around 18%, half on half. This should support a re-rating in the multiple at the 2019 results, in the broker's opinion. Buy rating and $30 target maintained.
UBS19/11/20191Buy$30.0022.95%COMMENTARYAppen has upgraded 2019...
Add APX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.01 |
Change
0.015(0.75%) |
Mkt cap ! $508.3M | |||
| Open | High | Low | Value | Volume |
| $2.02 | $2.04 | $1.94 | $11.97M | 6.024M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18754 | $2.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 49442 | 1 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| APX (ASX) Chart |